First-Line Treatment of Stage I/II DLBCL

Opinion
Video

A hematologist-oncologist joins the Oncology Brothers do discuss first-line treatment practices for patients with stage I or II diffuse large B-cell lymphoma.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
      Highlighting “Trickle-Down” Progress in Developing Rare Lymphoma Treatment
      The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
      Perseverance Underscores Success in Rare Lymphoma Research
      Increasing the use of patient-reported outcomes may ensure that practitioners can fully ascertain the impact of treatment for rare lymphomas.
      Addressing Unmet Needs in Patients Undergoing Treatment for Rare Lymphomas
      Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
      Addressing Limitations to Clinical Trial Development for Lymphoma Treatment
      Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
      Outlining Ongoing Clinical Developments in Treatment for Rare Lymphomas
      A paucity of prospective, well-vetted data to guide therapy in patients with rare lymphomas may result in a reliance on expert consensus guidelines.
      Highlighting Challenges to Patient Treatment in Rare Lymphomas
      Frontline Setting of Pancreatic Cancer
      Frontline Setting of Pancreatic Cancer
      Treatment Algorithm for Metastatic Pancreatic Cancer
      Treatment Algorithm for Metastatic Pancreatic Cancer
      Role of Radiation in Pancreatic Cancer Treatment
      Role of Radiation in Pancreatic Cancer Treatment
      NGS and Germline Testing in Pancreatic Cancer
      NGS and Germline Testing in Pancreatic Cancer
      Related Content
      The FDA originally placed a clinical hold on the program for tab-cel in January 2025 due to Good Manufacturing Practice (GMP) compliance issues associated with a pre-license inspection of a third-party manufacturing facility.

      FDA Lifts Clinical Hold on Tabelecleucel in EBV+ Lymphoproliferative Disease

      Russ Conroy
      May 7th 2025
      Article

      Investigators can restart the phase 3 ALLELE trial assessing tabelecleucel for patients with EBV-related posttransplant lymphoproliferative disease.

      Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

      Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

      Viviana Cortiana, MS4;Yan Leyfman, MD
      May 12th 2025
      Podcast

      Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

      CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

      CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

      Tim Cortese
      April 25th 2025
      Article

      Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

      Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

      Highlighting Insights From the Marginal Zone Lymphoma Workshop

      Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
      February 17th 2025
      Podcast

      Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

      Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

      Elucidating the Clinical Landscape for Rare Lymphoma Treatment

      Roman Fabbricatore
      April 17th 2025
      Article

      Diagnostic developments using aberrances in biomarker testing may help enhance survival in patients with rare lymphoma subtypes.

      Synthetic Hypericin Achieves Treatment Success in Cutaneous T-Cell Lymphoma

      Synthetic Hypericin Achieves Treatment Success in Cutaneous T-Cell Lymphoma

      Tim Cortese
      April 16th 2025
      Article

      At the indication of the FDA and EMA, the phase 3 FLASH2 trial will further evaluate synthetic hypericin in early-stage cutaneous T-cell lymphoma.